Abiopharma

News list

Director Kelderman Kim 🟢 acquired 6.7K shares (2 derivative) of CONMED Corp (CNMD) at $53.83 Transaction Date: Sep 08, 2025 | Filing ID: 000040

Full text

News bot Sept. 9, 2025, 8:14 p.m.
🔍 Kelderman Kim (Director)

Company: CONMED Corp (CNMD)

Report Date: 2025-09-08
Transaction Summary:
- Total transactions: 2
- Derivative instruments: 2
- Holdings reported: 0
- Total shares acquired: 6,727
Detailed Transactions and Holdings:
- Acquired 500 shares of RSUs (Restricted Stock Units) (Derivative)
  Date: 2025-09-08 | Code: A | Expires: 2035-09-08 | Exercise: 2026-09-08 | equity_swap_involved: 0 | shares_owned_after: 500.00 | transaction_form_type: 4 | Footnotes: F1
- Acquired 6,227 shares of Options To Purchase Common Stock at $53.83 per share (Derivative)
  Date: 2025-09-08 | Code: A | Expires: 2035-09-08 | Exercise: 2026-09-08 | equity_swap_involved: 0 | shares_owned_after: 6,227.00 | transaction_form_type: 4 | Footnotes: F2
Footnotes:
- F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock, par value $0.01 per share of ConMed Corporation (the "Company") and will be subject to the terms and conditions of the Company's 2025 Long-Term Incentive Plan, with the RSUs generally vesting 100% after a one year period.
- F2: The stock options were granted under the 2025 Long-Term Incentive Plan of CONMED Corporation (the "Company) and generally vest 100% 1 year from the grant date.